CoChat
Sign Up
Cited by 96

The DOI matches its Crossref record.

Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study)

Kaneko, Yuko, Atsumi, Tatsuya, Tanaka, Yoshiya, Inoo, Masayuki, Kobayashi-Haraoka, Hitomi, Amano, Koichi, Miyata, Masayuki, Murakawa, Yohko, Yasuoka, Hidekata, Hirata, Shintaro, Nagasawa, Hayato, Tanaka, Eiichi, Miyasaka, Nobuyuki, Yamanaka, Hisashi, Yamamoto, Kazuhiko, Takeuchi, Tsutomu·2016·Annals of the Rheumatic Diseases
DOI 10.1136/annrheumdis-2015-208426
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2015-208426

Cites

Statistics

Figures

Figure 1 Patient disposition and study fl ow chart. IC, informed consent.
Figure 1 Patient disposition and study fl ow chart. IC, informed consent.CC-BY-NC · From the PDF
Figure 2 Clinical ef fi cacy results. Results over time for (A) percentage of patients achieving DAS28 remission, (B) percentage of patients achieving ACR20/50/70, (C) patients achieving remission according to DAS28, SDAI, CDAI and ACR/EULAR Boolean de fi ned criteria at weeks 24 and 52. DAS28, disease activity score for 28 joints; ACR, American College of Rheumatology; SDAI, simpli fi ed disease activity index; CDAI, clinical disease activity index; EULAR, European League against Rheumatism. *p<0.05.
Figure 2 Clinical ef fi cacy results. Results over time for (A) percentage of patients achieving DAS28 remission, (B) percentage of patients achieving ACR20/50/70, (C) patients achieving remission according to DAS28, SDAI, CDAI and ACR/EULAR Boolean de fi ned criteria at weeks 24 and 52. DAS28, disease activity score for 28 joints; ACR, American College of Rheumatology; SDAI, simpli fi ed disease activity index; CDAI, clinical disease activity index; EULAR, European League against Rheumatism. *p<0.05.CC-BY-NC · From the PDF
Figure 3 Structural outcome. (A) Cumulative probability plot of change from baseline to week 52 in van der Heijde-modi fi ed total Sharp scoring system (mTSS). (B) Percentage of patients with CRRP. (C) Mean CRP. CRRP, clinically relevant radiographic progression; DAS28, disease activity score for 28 joints; CRP, C-reactive protein. *p<0.05.
Figure 3 Structural outcome. (A) Cumulative probability plot of change from baseline to week 52 in van der Heijde-modi fi ed total Sharp scoring system (mTSS). (B) Percentage of patients with CRRP. (C) Mean CRP. CRRP, clinically relevant radiographic progression; DAS28, disease activity score for 28 joints; CRP, C-reactive protein. *p<0.05.CC-BY-NC · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 21

  1. Smolen, 2014, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update, Ann Rheum Dis, 73, 492, 10.1136/annrheumdis-2013-204573 · DOI
  2. Smolen, 2010, Treating rheumatoid arthritis to target: recommendations of an international task force, Ann Rheum Dis, 69, 631, 10.1136/ard.2009.123919 · DOI
  3. Takeuchi, 2011, Revolutionary change in rheumatoid arthritis management with biological therapy, Keio J Med, 60, 75, 10.2302/kjm.60.75 · DOI
  4. Favalli, 2014, Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an “anchor” drug?, Autoimmun Rev, 13, 1102, 10.1016/j.autrev.2014.08.026 · DOI
  5. Klareskog, 2004, Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial, Lancet, 363, 675, 10.1016/S0140-6736(04)15640-7 · DOI · Paper page
  6. Kameda, 2011, Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study, J Rheumatol, 38, 1585, 10.3899/jrheum.110014 · DOI
  7. Breedveld, 2006, Arthritis Rheum, 54, 26, 10.1002/art.21519 · DOI
  8. Jones, 2010, Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study, Ann Rheum Dis, 69, 88, 10.1136/ard.2008.105197 · DOI · Paper page
  9. Nishimoto, 2009, Mod Rheumatol, 19, 12, 10.3109/s10165-008-0125-1 · DOI
  10. Burmester, 2013, Tocilizumab (TCZ) in combination and monotherapy versus methotrexate (MTX) in MTX-naïve patients (PTS) with early rheumatoid arthritis (RA): Clinical and radiographic outcomes from a randomized, placebo-controlled trial, Ann Rheum Dis, 72, A63, 10.1136/annrheumdis-2013-eular.246 · DOI
  11. Dougados, 2013, Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY), Ann Rheum Dis, 72, 43, 10.1136/annrheumdis-2011-201282 · DOI
  12. Dougados, 2014, Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study, Ann Rheum Dis, 73, 803, 10.1136/annrheumdis-2013-204761 · DOI
  13. Weinblatt, 2013, Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study, Arthritis Care Res (Hoboken), 65, 362, 10.1002/acr.21847 · DOI
  14. Nishimoto, 2010, Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions, Mod Rheumatol, 20, 222, 10.3109/s10165-010-0279-5 · DOI
  15. Maini, 2006, Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate, Arthritis Rheum, 54, 2817, 10.1002/art.22033 · DOI · Paper page
  16. Yamanaka, 2014, Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial, Rheumatology (Oxford), 53, 904, 10.1093/rheumatology/ket465 · DOI
  17. Bykerk, 2012, Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice, Ann Rheum Dis, 71, 1950, 10.1136/annrheumdis-2011-201087 · DOI
  18. Kameda, 2014, Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients, Arthritis Care Res (Hoboken), 66, 1302, 10.1002/acr.22306 · DOI
  19. Tokuhira, 2012, Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis, Leuk Lymphoma, 53, 616, 10.3109/10428194.2011.625101 · DOI
  20. Ichikawa, 2013, Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression, Eur J Haematol, 91, 20, 10.1111/ejh.12116 · DOI
  21. Takahashi, 2014, Methotrexate polyglutamates in erythrocytes correlates with clinical response in Japanese patients with rheumatoid arthritis, Ann Rheum Dis, 73, 218, 10.1136/annrheumdis-2014-eular.3527 · DOI

Cited by

Sorted by citations

Metadata

Authors
Kaneko, Y., Atsumi, T., Tanaka, Y., Inoo, M., Kobayashi-Haraoka, H., Amano, K., Miyata, M., Murakawa, Y., Yasuoka, H., Hirata, S., Nagasawa, H., Tanaka, E., Miyasaka, N., Yamanaka, H., Yamamoto, K., & Takeuchi, T.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2016-11
Volume
75
Issue
11
Pages
1917-1923
ISSN
0003-4967
DOI
10.1136/annrheumdis-2015-208426
Cited by
96
References
0
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review